The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, awarded a $664,774 firm-fixed-price contract to US Biologic, Inc. for the development of a rapid-response oral influenza vaccine. This contract was awarded under a Broad Agency Announcement (BAA) that sought research and development of innovative medical countermeasures. The contract has a completion date of February 29, 2024 and was not set aside for any specific business type. The original solicitation was posted in February 2020 with a due date of October 2022, and the award was made in March 2020.
Generated 6/19/24, 9:48 AM